SOURCE: SciClone Pharmaceuticals, Inc.

September 25, 2006 06:30 ET

SciClone's New CEO Unveils Focused Global Strategic Vision

Presentation at UBS Global Life Sciences Conference at 9:30 am EDT Today

SAN MATEO, CA -- (MARKET WIRE) -- September 25, 2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that Friedhelm Blobel, Ph.D., SciClone's recently appointed President and Chief Executive Officer, will unveil a focused global strategic vision and upcoming milestones during his presentation at the UBS Global Life Sciences Conference at 9:30 am EDT today. To access the live audio webcast of the presentation, log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com. A replay of the webcast will be available until October 25, 2006.

"I joined SciClone in June of this year, primarily because it is one of the few biotech companies with an established business generating significant sales in China," commented Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer. "Through our new global strategic vision, we intend to build on this core differentiating asset and expand our global product portfolio for the U.S., Europe and China."

SciClone's strategic goal is to:

-- Build a leading pharmaceutical business in China, one of the world's fastest growing pharmaceutical markets. Over the past decade, SciClone has established a successful sales and marketing organization which includes over 120 dedicated Chinese medical representatives calling on over 500 private hospitals in major cities throughout the country. As a result, today ZADAXIN is one of the top-selling imported pharmaceutical products in China. SciClone intends to build on its local expertise by expanding its abilities to conduct GCP-quality clinical trials and file regulatory documents in China. To add to its product portfolio, SciClone has recently acquired the Chinese marketing rights to DC Bead™ and intends to partner with U.S. and European biotechnology companies to develop and market their products in China.

-- Develop a global product portfolio for the U.S., Europe and China. With ongoing ZADAXIN trials in malignant melanoma (phase 2) and hepatitis C (phase 3), SciClone intends to develop ZADAXIN for regulatory approvals in the U.S. and Europe. Additionally, SciClone is evaluating the optimal development strategy for its proprietary drug candidate SCV-07 and is seeking to in-license additional products for development in China, the U.S. and Europe.

Over the course of the next 12 months, SciClone's objective is to achieve the following milestones as it executes its strategy:

Expected Milestone                                                  Timing
------------------                                                  ------
Report additional phase 2 melanoma data                               4Q06

Filing for DC Bead in China                                           4Q06

Initiate trial for DC Bead in liver cancer                            1H07

In-license/acquire one new product in China                           2007

Initiate phase 3 melanoma clinical trial for ZADAXIN                  2007

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products, such as the DC Bead, to broaden its portfolio in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

The information above and in Dr. Blobel's presentation contains forward-looking statements including our expectations and beliefs regarding our strategic objectives and progress and results of our clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including our ability to achieve development and partnering objectives, the progress of ongoing and proposed trials and studies for ZADAXIN and SCV-07, unexpected adverse results to patients, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.

Contact Information

  • Corporate contact:
    Richard Waldron
    Chief Financial Officer
    SciClone Pharmaceuticals, Inc.
    650-358-3437